Project Details
Description
VKH disease is a vision threatening condition. The investigators consider that ozurdex intravitreal implant is an effective line of treatment in recurrent VKH posterior uveitis.
Layman's description
Baseline ,and postoperative 1 ,6 ,12 and 24 months full ophthalmic examination was done.
Procedure included intravitreal injection of Dexamethasone implant 0.7 mg (Ozurdex(®); Allergan, Inc, Irvine, CA)
Procedure included intravitreal injection of Dexamethasone implant 0.7 mg (Ozurdex(®); Allergan, Inc, Irvine, CA)
| Status | Finished |
|---|---|
| Effective start/end date | 1/01/17 → 22/11/19 |
Collaborative partners
- Benha University (lead)
- Ibn Nafees Medical Center
- Abu Dhabi Health Services Company
Keywords
- Dexamethasone
- VKH
- Uveal Diseases
- Eye Diseases
- Panuveitis
- Uveitis
- Posterior Uveitis
- Anti-Inflammatory Agents
- Antiemetics
- Autonomic Agents
- Peripheral Nervous System Agents
- Physiological Effects of Drugs
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormone Substitutes
- Hormone Antagonists
- Antineoplastic Agents
- Hormonal Antineoplastic Agents
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.